Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

296 INFLUENZA VACCINES
(2002): Piedra PA+, Pediatrics 110(4), 662
(2002): Yanai-Berar N+, Clin Nephrol 58(3), 220 (1 case)
(2001): NEnglJMed345(21), 1529
(2000): Larner AJ+, Eur J Neurol 7(6), 731
Neurotoxicity
(2003): Shoji H+, Intern Med 42(2), 139
Rhabdomyolysis
(2000): Plotkin E+, NephrolDialTransplant15(5), 740 (with
cerivastatin and bezafibrate)
Systemic reactions (injection site)
(2002): Halperin SA+, Vaccine 20(7-8), 1240 (10–12%)
(2001): Allsup SJ+, Gerontology 47(6), 311 (5%)
(2001): Pregliasco F+, Aging (Milano) 13(1), 38
(2001): Zangwill KM+, Pediatr Infect Dis J 20(8), 740
(2000): Gonzalez M+, Arch Dis Child 2000 Dec; 83(6), 488
(mild)
Note: Inactivated influenza vaccine should not be given to persons
with anaphylactic hypersensitivity to eggs or other components of the
vaccine. For current data on influenza consult http://www.cdc.gov/flu
*Note: Oculorespiratory syndrome (ORS) is defined as the presence
of bilateral conjunctivitis, facial edema, or respiratory symptoms
occurring between 2 and 24h following immunization
INH
(See ISONIAZID)
INSULIN
Trade names: Humalog; Huminsulin; Humulin (Lilly); Iletin
Lente (Lilly); Insuman; Monotard; Novolin R (Novo Nordisk);
Velosulin (Novo Nordisk); Velosuline Humaine
Indications: Diabetes
Category: Hormone, polypeptide
Half-life: N/A
Duration of action: 5–28 hours
Clinically important, potentially hazardous interactions
with: alcohol, dimercaprol, ethanolamine, eucalyptus,
guanethidine, hydrocortisone, pegvisomant, propranolol,
sermorelin, vidarabine
Note: About 25% of patients with insulin allergy have a concomitant
history of penicillin allergy
Reactions
Skin
Allergic reactions (sic) (local)
(2002): Lee AY+, Acta Derm Venereol 82(2), 114
(1989): Zinman B, NEnglJMed321, 363
(1988): Plantin P+, Ann Dermatol Venereol (French) 115, 813
(>5%)
(1985): Bruni B+, Diabetes Care 8, 201
(1984): Grammer LC+, JAMA 251, 1459
(1982): Carveth-Johnson AO+, Lancet 2, 1287
(1982): Patterson R+, JAMA 248, 2637 (passim)
(1981): Hasche H+, Dtsch Med Wochenschr (German) 106, 1451
(1981): Kahn CB, Handbook of Diabetes Mellitus Garland
STPM, 75
(1980): Jegasothy BV, Int J Dermatol 19, 139 (immediate and
delayed) (10–56%)
Angioedema
(1983): Grammer LC+, J Allergy Clin Immunol 71, 250
(1981): Kahn CB, Handbook of Diabetes Mellitus Garland
STPM, 75
Atrophy
Bullous dermatitis
Dermatitis
(1994): Goldfine AB+, Curr Ther Endocrinol Metab 5, 461
(1989): Geldof BA+, Contact Dermatitis 20, 384
Diaphoresis (1–10%)
Edema (1–10%)
(2004): Kalambokis G+, J Endocrinol Invest 27(10), 957
(2004): Kalambokis GN+, Am J Kidney Dis 44(4), 575
(1981): Galloway JA+, Diabetes Mellitus Bowie 5, 117
Erythema
(2005): Wonders J+, Ned Tijdschr Geneeskd 149(50), 2783
Exanthems
Allergic granulomatous angiitis (Churg–Strauss syndrome)
(zinc)
(1989): Jordaan HF+, Clin Exp Dermatol 14, 227
Hematomas
(2003): Camata DG, Rev Lat Am Enfermagem 11(1), 119
Hyperkeratosis
(1989): Jordaan HF+, Clin Exp Dermatol 14, 277
(1986): Fleming MG+, Arch Dermatol 122, 1054 (resembling
acanthosis nigricans)
Keloid
Necrosis
Pallor (1–10%)
Pigmentation
Pigskin appearance
Pruritus (1–10%)
(2005): Wonders J+, Ned Tijdschr Geneeskd 149(50), 2783
(2002): Lee AY+, Acta Derm Venereol 82(2), 114
(1981): Knick B, Munch Med Wochenschr (German) 123, 1197
Purpura
Urticaria (1–10%)
(1996): Rowland-Payne CM+, Br J Dermatol 134, 184
(1995): Chng HH+, Allergy 50, 984
(1988): Plantin P+, Ann Dermatol Venereol (French) 115, 813
(1983): Grammer LC+, J Allergy Clin Immunol 71, 250
(1982): Mirouze J+, Nouv Presse Med (French) 11, 3121
(1982): Patterson R+, JAMA 248, 2637 (passim)
(1981): Kahn CB, Handbook of Diabetes Mellitus Garland
STPM, 75
Vasculitis
(2002): Mandrup-Poulsen T+, Diabetes Care 25(1), 242
(1983): Grammer LC+, J Allergy Clin Immunol 71, 250
Xanthomas
Other
Anaphylactoid reactions/Anaphylaxis (1–10%)
(2007): Kaya A+, J Diabetes Complications 21(2), 124 (fatal)
(2005): Wonders J+, Ned Tijdschr Geneeskd 149(50), 2783
(1983): Grammer LC+, J Allergy Clin Immunol 71, 250
(1982): Patterson R+, JAMA 248, 2637 (passim)
(1981): Kahn CB, Handbook of Diabetes Mellitus Garland
STPM, 75
Hypersensitivity
(2003): Wittrup M+, Ugeskr Laeger 165(21), 2207
(1983): Berman BA+, Cutis 32, 320
(1982): deShazo RD+, J Allergy Clin Immunol 69, 229
Hypertrophic lipodystrophy
(1983): Johnson DA+, Cutis 32, 273
Injection-site calcification
(1995): Ullman HR+, J Comput Assist Tomogr 19, 657
Injection-site cancer
Injection-site erythema
(2006): Moyes V+, Diabet Med 23(2), 204
Injection-site induration
(1983): White WB+, Am J Med 74, 909
(1981): Galloway JA+, Diabetes Mellitus Bowie 5, 117